Literature DB >> 1988119

Role of folylpolyglutamates in biochemical modulation of fluoropyrimidines by leucovorin.

A Romanini1, J T Lin, D Niedzwiecki, M Bunni, D G Priest, J R Bertino.   

Abstract

The growth-inhibitory effect of fluoropyrimidines combined with a short-term exposure to leucovorin and the pattern of polyglutamylation of folates were compared between parental CCRF-CEM cells and a cell line with impaired ability to form polyglutamates (CCRF-CEM/P). The combination of leucovorin with 5-fluorouracil or 5-fluorodeoxyuridine increased the growth inhibition of CCRF-CEM cells compared to the fluoropyrimidine alone in the parent cell line but not in CCRF-CEM/P cells. In addition, leucovorin produced a significant increase in the inhibition of intracellular thymidylate synthase activity caused by 5-fluorouracil or 5-fluorodeoxyuridine as compared to these drugs alone in CCRF-CEM cells, but no increase in inhibition over that produced by the single drugs alone was observed in CCRF-CEM/P cells. Although levels of 5,10-methylene tetrahydrofolate after leucovorin administration were similar in both cell lines, polyglutamylation of this coenzyme was decreased in the CCRF-CEM/P cell line. The inability of CCRF-CEM/P cells to form significant levels of polyglutamates of N5,N10-methylenete-trahydrofolate, may be responsible for the lack of enhanced cell kill observed when a short exposure to leucovorin is used with fluoropyrimidines.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1988119

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines.

Authors:  Y Sugimoto; Y Ohe; K Nishio; T Ohmori; Y Fujiwara; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Pharmacologic modulation of 5-fluorouracil by folinic acid and pyridoxine for treatment of patients with advanced breast carcinoma.

Authors:  David Machover; Emma Goldschmidt; Wathek Almohamad; Vincent Castagné; Julien Dairou; Christophe Desterke; Léa Gomez; Yann Gaston-Mathé; Claude Boucheix
Journal:  Sci Rep       Date:  2022-05-31       Impact factor: 4.996

3.  Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate.

Authors:  K-J Sohn; F Smirnakis; D N Moskovitz; P Novakovic; Z Yates; M Lucock; R Croxford; Y-I Kim
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

4.  Pharmacologic modulation of 5-fluorouracil by folinic acid and high-dose pyridoxine for treatment of patients with digestive tract carcinomas.

Authors:  David Machover; Wathek Almohamad; Vincent Castagné; Christophe Desterke; Léa Gomez; Yann Gaston-Mathé; Claude Boucheix; Emma Goldschmidt
Journal:  Sci Rep       Date:  2021-06-16       Impact factor: 4.379

5.  The effect of dose and interval between 5-fluorouracil and leucovorin on the formation of thymidylate synthase ternary complex in human cancer cells.

Authors:  J C Drake; D M Voeller; C J Allegra; P G Johnston
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

6.  Low expression of gamma-glutamyl hydrolase mRNA in primary colorectal cancer with the CpG island methylator phenotype.

Authors:  K Kawakami; A Ooyama; A Ruszkiewicz; M Jin; G Watanabe; J Moore; T Oka; B Iacopetta; T Minamoto
Journal:  Br J Cancer       Date:  2008-04-15       Impact factor: 7.640

7.  γ-Glutamyl hydrolase modulation and folate influence chemosensitivity of cancer cells to 5-fluorouracil and methotrexate.

Authors:  S-E Kim; P D Cole; R C Cho; A Ly; L Ishiguro; K-J Sohn; R Croxford; B A Kamen; Y-I Kim
Journal:  Br J Cancer       Date:  2013-09-17       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.